logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2019 – Isatuximab improves progression-free survival in patients with relapsed/refractory multiple myeloma

Data from ICARIA-MM trial suggest that the addition of isatuximab to pomalidomide/dexamethasone results in a clinically meaningful improvement in survival